Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Harvard_Psilocybin_Project
gptkb:Terence_Mc_Kenna gptkb:Liberty_Cap gptkb:liberty_cap gptkb:The_Politics_of_Ecstasy gptkb:magic_mushrooms gptkb:Magic_Mushroom |
| gptkbp:affects |
time distortion
hallucinations enhanced creativity altered perception visual distortions enhanced emotional experiences altered thought processes increased introspection |
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:composed_of |
can be synthesized in a lab
|
| gptkbp:cultural_practices |
recreational use
spiritual rituals shamanic practices |
| gptkbp:discovered_by |
gptkb:Albert_Hofmann
|
| gptkbp:duration |
4 to 6 hours
|
| gptkbp:historical_source |
certain species of mushrooms
|
| https://www.w3.org/2000/01/rdf-schema#label |
psilocybin
|
| gptkbp:ingredients |
C12 H17 N2 O4 P
|
| gptkbp:is_used_for |
treatment of depression
treatment of anxiety treatment of PTSD |
| gptkbp:legal_issue |
varies by country
|
| gptkbp:manager |
oral
|
| gptkbp:notable_work |
Imperial College London research
Johns Hopkins University research MAPS research NYU Langone Health research UCLA research |
| gptkbp:occurs_in |
found in over 200 species of mushrooms
|
| gptkbp:premiered_on |
20 to 40 minutes
|
| gptkbp:previous_name |
3-(2-dimethylaminoethyl)-1 H-indol-4-yl dihydrogen phosphate
|
| gptkbp:products |
gptkb:psilocin
|
| gptkbp:public_perception |
associated with counterculture
gaining acceptance increasing interest in mental health treatment |
| gptkbp:related_concept |
gptkb:DMT
LSD mescaline |
| gptkbp:research_areas |
psychiatry
|
| gptkbp:safety_features |
generally considered safe in controlled settings
|
| gptkbp:scientific_classification |
Schedule I controlled substance in the US
|
| gptkbp:side_effect |
anxiety
dizziness nausea confusion |
| gptkbp:social_structure |
phosphate group
indole ring |
| gptkbp:weight |
284.25 g/mol
|
| gptkbp:year_created |
gptkb:1958
|